Author:
Conner Sydney J.,Guarin Justinne R.,Le Thanh T.,Fatherree Jackson P.,Kelley Charlotte,Payne Samantha L.,Parker Savannah R.,Bloomer Hanan,Zhang Crystal,Salhany Kenneth,McGinn Rachel A.,Henrich Emily,Yui Anna,Srinivasan Deepti,Borges Hannah,Oudin Madeleine J.
Abstract
Abstract
Background
Metastasis is the leading cause of death in breast cancer patients. For metastasis to occur, tumor cells must invade locally, intravasate, and colonize distant tissues and organs, all steps that require tumor cell migration. The majority of studies on invasion and metastasis rely on human breast cancer cell lines. While it is known that these cells have different properties and abilities for growth and metastasis, the in vitro morphological, proliferative, migratory, and invasive behavior of these cell lines and their correlation to in vivo behavior is poorly understood. Thus, we sought to classify each cell line as poorly or highly metastatic by characterizing tumor growth and metastasis in a murine model of six commonly used human triple-negative breast cancer xenografts, as well as determine which in vitro assays commonly used to study cell motility best predict in vivo metastasis.
Methods
We evaluated the liver and lung metastasis of human TNBC cell lines MDA-MB-231, MDA-MB-468, BT549, Hs578T, BT20, and SUM159 in immunocompromised mice. We characterized each cell line's cell morphology, proliferation, and motility in 2D and 3D to determine the variation in these parameters between cell lines.
Results
We identified MDA-MB-231, MDA-MB-468, and BT549 cells as highly tumorigenic and metastatic, Hs578T as poorly tumorigenic and metastatic, BT20 as intermediate tumorigenic with poor metastasis to the lungs but highly metastatic to the livers, and SUM159 as intermediate tumorigenic but poorly metastatic to the lungs and livers. We showed that metrics that characterize cell morphology are the most predictive of tumor growth and metastatic potential to the lungs and liver. Further, we found that no single in vitro motility assay in 2D or 3D significantly correlated with metastasis in vivo.
Conclusions
Our results provide an important resource for the TNBC research community, identifying the metastatic potential of 6 commonly used cell lines. Our findings also support the use of cell morphological analysis to investigate the metastatic potential and emphasize the need for multiple in vitro motility metrics using multiple cell lines to represent the heterogeneity of metastasis in vivo.
Funder
National Cancer Institute
National Institute of Diabetes and Digestive and Kidney Diseases
Breast Cancer Alliance
Publisher
Springer Science and Business Media LLC
Reference47 articles.
1. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7–33. https://doi.org/10.3322/caac.21708.
2. Moss JL, Tatalovich Z, Zhu L, Morgan C, Cronin KA. Triple-negative breast cancer incidence in the United States: ecological correlations with area-level sociodemographics, healthcare, and health behaviors. Breast Cancer. 2021;28(1):82–91. https://doi.org/10.1007/s12282-020-01132-w.
3. Kaplan D, Overview of the Updated NCCN Guidelines on Triple-Negative Breast Cancer HMP Glob. Learn. Netw., Dec. 2021, Accessed: Feb. 05, 2023. [Online]. Available: https://www.hmpgloballearningnetwork.com/site/jcp/jcp-special-report/overview-updated-nccn-guidelines-triple-negative-breast-cancer
4. Bianchini G, Balko JM, Mayer IA, Sanders ME, Gianni L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat Rev Clin Oncol. 2016. https://doi.org/10.1038/nrclinonc.2016.66.
5. Anders CK, Zagar TM, Carey LA. The management of early-stage and metastatic triple-negative breast cancer: a review. Hematol Oncol Clin North Am. 2013;27(4):737–49. https://doi.org/10.1016/j.hoc.2013.05.003.